The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 1, 2011, Pages 99-105

  Scarpellini, E ^a   Vos, R ^a   Blondeau, K ^a   Boecxstaens, V ^a   Farre R ^a   Gasbarrini, A ^a   Tack, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ITOPRIDE; PLACEBO; PROKINETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ESOPHAGUS FUNCTION; ESOPHAGUS MANOMETRY; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; NORMAL HUMAN; PERISTALSIS; POSTPRANDIAL STATE; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADULT; BENZAMIDES; BENZYL COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ESOPHAGEAL SPHINCTER, LOWER; FASTING; FEMALE; GASTRIC EMPTYING; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650025715     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04487.x     Document Type: Article

References (23)

1. Iwanaga Y, Kimura T, Miyashita N, et al. Characterization of acetylcholinesterase-inhibition by itopride. J J Pharmacol 1994; 66: 317-22.
2. Iwanaga Y, Miyashita N, Saito T, Morikawa K, Itoh Z,. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. J J Pharmacol 1996; 71: 129-37.
3. Cellek S, Sanger G,. potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. Pharm Res 2008; 58: 297-301.
4. Stevens J, Russo A, Maddox A, et al. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastro Motil 2008; 20: 456-63.
5. Choung R, Talley N, Peterson J, et al. Trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007; 19: 180-7.
6. Holtmann G, Talley N, Liebregts T, Adam B, Parow C,. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-40.
7. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M,. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57: 740-6.
8. Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
9. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005; 11: 4210-4.
10. Ang D, Sifrim D, Tack J,. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 383-92.
11. Tack J, Sifrim D,. Anti-relaxation therapy in GORD. Gut 2002; 50: 6-7.
12. Tack J,. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease. Curr Opin Gastroenterol 2005; 21: 454-60.
13. Boeckxstaens GE,. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008; 8: 685-9.
14. Holloway RH, Penagini R, Ireland AC,. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268: G128-33.
15. Choung RS, Talley NJ, Peterson J, et al. A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers. Neurogastroenterol Motil 2007; 19: 180-7.
16. Akyuz F, Mimidis K, Nikolai H, Vos R, Tack J,. Influence of itopride and domperidone on gastric tone and on the perception of gastric distention in healthy subjects. Gastroenterology 2007; 132: A688.
17. Katagiri F, Shiga T, Inoue S, Sato Y, Itoh H, Takeyama M,. Effects of itopride hydrochloride on plasma gut-regulatory peptide and stress-related hormone levels in healthy human subjects. Pharmacology 2006; 77: 115-21.
18. Ramirez B, Richter JE,. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5-20.
19. Pritchard DS, Baber N, Stephenson T,. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59: 725-9.
20. Grande L, Lacima G, Ros E, et al. Lack of effect of metoclopramide and domperidone on esophageal peristalsis and esophageal acid clearance in reflux esophagitis. A randomized, double-blind study. Dig Dis Sci 1992; 37: 583-8.
21. Di Stefano M, Vos R, Klersy C, Lee KJ, Janssens J, Tack J,. Neostigmine-induced postprandial phasic contractility in the proximal stomach and dyspepsia-like symptoms in healthy volunteers. Am J Gastroenterol 2006; 101: 2797-804.
22. Fang JC, Sarosiek I, Yamamoto Y, Liu J, Mittal RK,. Cholinergic blockade inhibits gastro-oesophageal reflux and transient lower oesophageal sphincter relaxation through a central mechanism. Gut 1999; 44: 603-7.
23. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH,. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118: 7-13.